Pharma News

Human brain is one of the most powerful and intelligent natural computer known to mankind. Neuromorphic computing refers to the field of technology where engineers try to build intelligent machines inspired from the working of mammal brains. Neurons and synapses are believed to be the most important building blocks giving rise to intelligence inside brains.

Roche announced that Venclexta in combination with azacitidine has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes based on the revised International Prognostic Scoring System . MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells. This can lead to weakness, frequent infections, anaemia and debilitating fatigue.

Junshi Biosciences a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA te

Roche announced that Japans Ministry of Health, Labour and Welfare has approved Ronapreve  casirivimab and imdevimab, for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act.

Integra Life Sciences Holding Corporation a leading global medical technology company announced positive clinical outcomes for PriMatrix Dermal Repair Scaffold for the management of hard to heal diabetic foot ulcers. This study is one of the largest DFU randomized controlled trials ever completed with more than 100 patients per treatment group and demonstrated that in most cases, one application of PriMatrix plus standard of care healed 60% of DFUs in 12 weeks versus 35% of DFUs that healed in 12 weeks with SOC for the per protocol analysis.

PLx Pharma Inc a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products, with its lead products VAZALORE 325 mg and VAZALORE 81 mg ,referred to together as VAZALORE, announced that three stock-keeping units of VAZALORE, the first and only U.S. Food and Drug Administration approved liquid-filled aspirin capsules, will be available in over 8,000 Walgreens stores nationwide later in August. Walgreens is a global leader in retail pharmacy.

Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland.

Writing in the journal Nature Immunology, they detail an investigation into one of the key features of adenovirus vaccines – their ability to generate strong and sustained populations of the ‘killer’ T-cell element of the immune system.

Improvisation of the Pharmacopeia and capacity building with CSIR and IITs are the major focus areas for promoting Innvoations in AYUSH Sector said by Dr. Manoj Nesari, Advisor, Ministry of AYUSH, Govt. of India.

AYUSH Committee, PHDCCI organized a Webinar on Innovation & Entrepreneurship in AYUSH Sector- Role of Industry and Govt. of India on 15th July 2021.

BONE THERAPEUTICS the cell therapy company addressing unmet medical needs in orthopedics and other diseases provides an update on its two leading ongoing clinical studies.

These studies are the pivotal Phase III clinical trial with Bone Therapeutics’ enhanced viscosupplement, JTA-004, targeting osteoarthritic knee pain, and the Phase IIb study with its allogeneic cell therapy product, ALLOB, in patients with difficult-to-heal tibial fractures.